Timing of response with venetoclax combination treatment in patients with newly diagnosed acute myeloid leukemia

Brian A. Jonas; Andrew H. Wei; Christian Recher; Courtney D. DiNardo; Jun Ho Jang; Keith Pratz; Panayiotis Panayiotidis; Pau Montesinos; Su Peng Yeh; Vladimir Ivanov; Walter Fiedler; Takahiro Yamauchi; Yinghui Duan; Wellington Mendes; Jalaja Potluri; Björn Tews; Yishai Ofran

doi:10.1002/ajh.26600

Timing of response with venetoclax combination treatment in patients with newly diagnosed acute myeloid leukemia

Brian A. Jonas, Andrew H. Wei, Christian Recher, Courtney D. DiNardo, Jun Ho Jang, Keith Pratz, Panayiotis Panayiotidis, Pau Montesinos, Su Peng Yeh, Vladimir Ivanov, Walter Fiedler, Takahiro Yamauchi, Yinghui Duan, Wellington Mendes, Jalaja Potluri, Björn Tews, Yishai Ofran

Leukemia

Research output: Contribution to journal › Letter › peer-review

5 Scopus citations

Original language	English (US)
Pages (from-to)	E299-E303
Journal	American journal of hematology
Volume	97
Issue number	8
DOIs	https://doi.org/10.1002/ajh.26600
State	Published - Aug 2022

ASJC Scopus subject areas

Hematology

Access to Document

10.1002/ajh.26600

Cite this

Jonas, B. A., Wei, A. H., Recher, C., DiNardo, C. D., Jang, J. H., Pratz, K., Panayiotidis, P., Montesinos, P., Yeh, S. P., Ivanov, V., Fiedler, W., Yamauchi, T., Duan, Y., Mendes, W., Potluri, J., Tews, B., & Ofran, Y. (2022). Timing of response with venetoclax combination treatment in patients with newly diagnosed acute myeloid leukemia. American journal of hematology, 97(8), E299-E303. https://doi.org/10.1002/ajh.26600

Jonas, BA, Wei, AH, Recher, C, DiNardo, CD, Jang, JH, Pratz, K, Panayiotidis, P, Montesinos, P, Yeh, SP, Ivanov, V, Fiedler, W, Yamauchi, T, Duan, Y, Mendes, W, Potluri, J, Tews, B & Ofran, Y 2022, 'Timing of response with venetoclax combination treatment in patients with newly diagnosed acute myeloid leukemia', American journal of hematology, vol. 97, no. 8, pp. E299-E303. https://doi.org/10.1002/ajh.26600

@article{c3a60d723c7540318b8b68550caf96bc,

title = "Timing of response with venetoclax combination treatment in patients with newly diagnosed acute myeloid leukemia",

author = "Jonas, {Brian A.} and Wei, {Andrew H.} and Christian Recher and DiNardo, {Courtney D.} and Jang, {Jun Ho} and Keith Pratz and Panayiotis Panayiotidis and Pau Montesinos and Yeh, {Su Peng} and Vladimir Ivanov and Walter Fiedler and Takahiro Yamauchi and Yinghui Duan and Wellington Mendes and Jalaja Potluri and Bj{\"o}rn Tews and Yishai Ofran",

note = "Funding Information: reports consultancy/advisory role for AbbVie, BMS, Genentech, Gilead, GlycoMimetics, Jazz, Pfizer, Servier, Takeda, Tolero, and Treadwell; protocol steering committee for GlycoMimetics; data monitoring committee for Gilead; travel support from AbbVie; research funding to institution from 47, AbbVie, Accelerated Medical Diagnostics, Amgen, AROG, BMS, Celgene, Daiichi Sankyo, F. Hoffmann‐La Roche, Forma, Genentech/Roche, Gilead, GlycoMimetics, Hanmi, Immune‐Onc, Incyte, Jazz, Loxo, LP Therapeutics, Pfizer, Pharmacyclics, Sigma Tau, and Treadwell. reports consultancy/advisory role for Novartis, Janssen, Amgen, Roche, Pfizer, AbbVie, Servier, Gilead, BMS, Macrogenics and Agios; speakers' bureau participation for AbbVie, Novartis, and BMS; royalties from the Walter and Eliza Hall Institute of Medical Research related to venetoclax; research funding to institution from Novartis, AbbVie, Servier, BMS, AstraZeneca, and Amgen. reports consultancy/advisory role for AbbVie, Janssen, Jazz Pharmaceuticals, Novartis, Celgene, Otsuka, Astellas, Daiichi‐Sankyo, Macrogenics, Roche, Takeda, and Pfizer; research funding from AbbVie, Amgen, Novartis, Celgene, Jazz Pharmaceuticals, Agios, Chugai, MaatPharma, Astellas, Roche, Iqvia, and Daiichi‐Sankyo. reports consultancy/advisory role for AbbVie, Agios, Aprea, Celgene/BMS, ImmuneOnc, Kura, Novartis, Takeda, and Notable Labs; research funding to institution from AbbVie, Agios, Calithera, Cleave, BMS/Celgene, Daiichi‐Sankyo, ImmuneOnc, and Loxo. declares no conflicts to disclose. reports consultancy/advisory role for AbbVie, Astellas, Boston BioMedical, Bristol Myers Squibb, Novartis, Servier, Jazz Pharmaceuticals, and Celgene; research funding from AbbVie, Agios, Daiichi Sankyo, and Millennium. reports honoraria from AbbVie, Amgen, Celgene, Roche, Genesis, Novartis, Gilead, and Janssen; research funding from AbbVie, Genesis, and Roche. reports consultancy/advisory role, speakers' bureau participation, and research funding from AbbVie. reports consultancy/advisory role for AbbVie, Amgen, Janssen, Astellas, Astex, and Takeda. reports being a clinical investigator in clinical trials for AbbVie, Pfizer, MSD, Takeda, ABScience, Ascentage Pharma Group, Astellas, Novartis, and GSK. reports consultancy/advisory role for AbbVie, Amgen, ARIAD, Celgene, Clinigen, Jazz Pharmaceuticals, Novartis, Stemline, Morphosys, Servier, and Pfizer; patents, royalties, or other intellectual property from a patent on immunotherapy in AML obtained together with Amgen; travel support from Amgen, Daiichi Sankyo, Jazz Pharmaceuticals, and Servier; research funding from Amgen. reports honoraria from Pfizer, AbbVie, Nihon‐Shin‐Yaku, Astellas, and Pfizer; consultancy/advisory role for Janssen, Novartis, and Pfizer; research funding from Chugai, Pfizer, and Solasia. report employment with AbbVie and may hold stock or other options. reports honoraria from AbbVie; consultancy/advisory role for AbbVie, Pfizer, Takeda, JnJ, Amgen, Astellas, Novartis, and Roche. B.A.J. A.H.W. C.R. C.D.D. J‐H.J. K.P. P.P. P.M. S‐P.Y. V.I. W.F. T.Y. Y.D., W.M., J.P., and B.T. Y.O. ",

year = "2022",

month = aug,

doi = "10.1002/ajh.26600",

language = "English (US)",

volume = "97",

pages = "E299--E303",

journal = "American journal of hematology",

issn = "0361-8609",

publisher = "Wiley-Liss Inc.",

number = "8",

}

TY - JOUR

T1 - Timing of response with venetoclax combination treatment in patients with newly diagnosed acute myeloid leukemia

AU - Jonas, Brian A.

AU - Wei, Andrew H.

AU - Recher, Christian

AU - DiNardo, Courtney D.

AU - Jang, Jun Ho

AU - Pratz, Keith

AU - Panayiotidis, Panayiotis

AU - Montesinos, Pau

AU - Yeh, Su Peng

AU - Ivanov, Vladimir

AU - Fiedler, Walter

AU - Yamauchi, Takahiro

AU - Duan, Yinghui

AU - Mendes, Wellington

AU - Potluri, Jalaja

AU - Tews, Björn

AU - Ofran, Yishai

N1 - Funding Information: reports consultancy/advisory role for AbbVie, BMS, Genentech, Gilead, GlycoMimetics, Jazz, Pfizer, Servier, Takeda, Tolero, and Treadwell; protocol steering committee for GlycoMimetics; data monitoring committee for Gilead; travel support from AbbVie; research funding to institution from 47, AbbVie, Accelerated Medical Diagnostics, Amgen, AROG, BMS, Celgene, Daiichi Sankyo, F. Hoffmann‐La Roche, Forma, Genentech/Roche, Gilead, GlycoMimetics, Hanmi, Immune‐Onc, Incyte, Jazz, Loxo, LP Therapeutics, Pfizer, Pharmacyclics, Sigma Tau, and Treadwell. reports consultancy/advisory role for Novartis, Janssen, Amgen, Roche, Pfizer, AbbVie, Servier, Gilead, BMS, Macrogenics and Agios; speakers' bureau participation for AbbVie, Novartis, and BMS; royalties from the Walter and Eliza Hall Institute of Medical Research related to venetoclax; research funding to institution from Novartis, AbbVie, Servier, BMS, AstraZeneca, and Amgen. reports consultancy/advisory role for AbbVie, Janssen, Jazz Pharmaceuticals, Novartis, Celgene, Otsuka, Astellas, Daiichi‐Sankyo, Macrogenics, Roche, Takeda, and Pfizer; research funding from AbbVie, Amgen, Novartis, Celgene, Jazz Pharmaceuticals, Agios, Chugai, MaatPharma, Astellas, Roche, Iqvia, and Daiichi‐Sankyo. reports consultancy/advisory role for AbbVie, Agios, Aprea, Celgene/BMS, ImmuneOnc, Kura, Novartis, Takeda, and Notable Labs; research funding to institution from AbbVie, Agios, Calithera, Cleave, BMS/Celgene, Daiichi‐Sankyo, ImmuneOnc, and Loxo. declares no conflicts to disclose. reports consultancy/advisory role for AbbVie, Astellas, Boston BioMedical, Bristol Myers Squibb, Novartis, Servier, Jazz Pharmaceuticals, and Celgene; research funding from AbbVie, Agios, Daiichi Sankyo, and Millennium. reports honoraria from AbbVie, Amgen, Celgene, Roche, Genesis, Novartis, Gilead, and Janssen; research funding from AbbVie, Genesis, and Roche. reports consultancy/advisory role, speakers' bureau participation, and research funding from AbbVie. reports consultancy/advisory role for AbbVie, Amgen, Janssen, Astellas, Astex, and Takeda. reports being a clinical investigator in clinical trials for AbbVie, Pfizer, MSD, Takeda, ABScience, Ascentage Pharma Group, Astellas, Novartis, and GSK. reports consultancy/advisory role for AbbVie, Amgen, ARIAD, Celgene, Clinigen, Jazz Pharmaceuticals, Novartis, Stemline, Morphosys, Servier, and Pfizer; patents, royalties, or other intellectual property from a patent on immunotherapy in AML obtained together with Amgen; travel support from Amgen, Daiichi Sankyo, Jazz Pharmaceuticals, and Servier; research funding from Amgen. reports honoraria from Pfizer, AbbVie, Nihon‐Shin‐Yaku, Astellas, and Pfizer; consultancy/advisory role for Janssen, Novartis, and Pfizer; research funding from Chugai, Pfizer, and Solasia. report employment with AbbVie and may hold stock or other options. reports honoraria from AbbVie; consultancy/advisory role for AbbVie, Pfizer, Takeda, JnJ, Amgen, Astellas, Novartis, and Roche. B.A.J. A.H.W. C.R. C.D.D. J‐H.J. K.P. P.P. P.M. S‐P.Y. V.I. W.F. T.Y. Y.D., W.M., J.P., and B.T. Y.O.

PY - 2022/8

Y1 - 2022/8

UR - http://www.scopus.com/inward/record.url?scp=85131528200&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85131528200&partnerID=8YFLogxK

U2 - 10.1002/ajh.26600

DO - 10.1002/ajh.26600

M3 - Letter

C2 - 35567776

AN - SCOPUS:85131528200

SN - 0361-8609

VL - 97

SP - E299-E303

JO - American journal of hematology

JF - American journal of hematology

IS - 8

ER -

Timing of response with venetoclax combination treatment in patients with newly diagnosed acute myeloid leukemia

ASJC Scopus subject areas

Access to Document

Other files and links

Cite this